Mechanisms behind hyperglycemia-associated breast cancer risk and progression
高血糖相关乳腺癌风险和进展背后的机制
基本信息
- 批准号:8856136
- 负责人:
- 金额:$ 35.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-21 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAddressAffectAfrican AmericanAmericanApoptosisBRCA1 geneBreastBreast Cancer CellBreast Cancer PatientBreast Epithelial CellsCell Cycle ArrestCell ProliferationCellsComplexDNA DamageDevelopmentDiabetes MellitusDiabetic mouseDiagnosisDietDiseaseEP300 geneEpidemiologic StudiesEpidemiologyEpithelialEpithelial CellsEpitheliumEventFatty acid glycerol estersGene TargetingGenetic TranscriptionGlucoseGoalsHispanicsHyperglycemiaIncidenceLatinaLightLinkMCF10A cellsMCF7 cellMalignant NeoplasmsMolecularNoxaeNuclearNude MiceOncogenicOutcomePathway interactionsPatientsPhosphoric Monoester HydrolasesPhosphorylationPlayProcessProtein p53Quality of lifeRiskRisk FactorsRoleSignal TransductionSocietiesSpecimenStagingStreptozocinTestingTimeTumor Suppressor ProteinsWomanbasecancer riskchemotherapyclinically relevantdiabetichealth disparityimprovedin vivoinsightmalignant breast neoplasmmortalityneoplastic cellnovelpublic health relevancetargeted treatmenttumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Epidemiologic evidence suggests that women with diabetes have increased risk of breast cancer and that diabetes may dramatically increase mortality in patients with cancer. Importantly, African-American and Hispanic/Latina women are disproportionately affected by diabetes and its complications. Concurrently, these women have worst outcome from breast cancer. Diabetes and cancer share many risk factors, but potential biologic links between the two diseases are incompletely understood. Our preliminary studies have provided new insights into how high glucose (HG) functions in breast epithelial cells. Exposure of cultured transformed (MCF-7) and normal (MCF-10A) breast epithelial cells to clinically relevant levels of glucose dramatically suppresses the tumor suppressor p53 acetylation, and, consequently, additively promotes tumor cell proliferation and abrogates DNA damage-induced apoptosis. Importantly, activation of nuclear phosphatase PP2Cd plays a role in this process. In addition, we for the first time demonstrate that BRAC1 forms a complex with p300 and p53, and an increased phosphorylation of BRAC1 by DNA damage enhances the recruitment of p53 to p300 and facilitates subsequent p53 acetylation. Upon activation by HG, PP2Cd dephosphorylates BRAC1 and inhibits its up-regulatory effect on p53 acetylation. These results may not only provide explanation for increased epithelial proliferation and tumorigenesis by hyperglycemia, but also increased breast cancer risk by diabetes. Based on these results we hypothesize that hyperglycemia, via a pathway that involved in PP2Cd activation, suppresses the tumor suppressor BRCA1 and p53 function and inhibits DNA damage-induced apoptosis and cell cycle arrest, inducing proliferation in the epithelium and the initiation and development of breast cancer. This hypothesis will be tested in three specific aims: (1) To explore the mechanisms underlying HG-induced PP2Cd activation; (2) To investigate the molecular mechanism by which PP2Cd dephosphorylates BRAC1 and antagonizes p53 acetylation in breast epithelial cells; (3) To characterize the effects of hyperglycemia on the development and chemotherapy of breast cancer in vivo using streptozotocin (STZ)-induced or high fat diet/STZ-induced diabetic nude mice bearing MCF-7 cells and breast cancer specimens from patients with or without diabetes. These studies set the stage for investigating this novel mechanism connecting diabetes and breast cancer with a goal of defining a new pathway and providing additional targets for therapy. Breast cancer in particular affects a large sector of African-American and Hispanic women and constitutes a significant financial burden for the society. Thus, studying the influence of hyperglycemia on oncogenic signaling networks is a novel question with considerable translational implications and would be a significant step in shedding light on this health disparity.
描述(由申请人提供):流行病学证据表明,患有糖尿病的女性患乳腺癌的风险增加,糖尿病可能会显著增加癌症患者的死亡率。重要的是,非洲裔美国人和西班牙裔/拉丁裔妇女不成比例地受到糖尿病及其并发症的影响。同时,这些妇女患乳腺癌的结果最差。糖尿病和癌症有许多共同的风险因素,但这两种疾病之间的潜在生物学联系尚不完全清楚。我们的初步研究为高葡萄糖(HG)如何在乳腺上皮细胞中发挥作用提供了新的见解。将培养的转化(MCF-7)和正常(MCF-10A)乳腺上皮细胞暴露于临床相关水平的葡萄糖显著抑制肿瘤抑制因子p53乙酰化,并且因此加成性地促进肿瘤细胞增殖并消除DNA损伤诱导的凋亡。重要的是,核磷酸酶PP 2Cd的激活在此过程中发挥作用。此外,我们首次证明BRAC 1与p300和p53形成复合物,并且通过DNA损伤增加BRAC 1的磷酸化增强了p53向p300的募集,并促进了随后的p53乙酰化。在被HG激活后,PP 2Cd使BRAC 1去磷酸化并抑制其对p53乙酰化的上调作用。这些结果不仅可以解释高血糖导致的上皮细胞增殖和肿瘤发生增加,而且还可以解释糖尿病导致的乳腺癌风险增加。基于这些结果,我们推测,高血糖,通过参与PP 2Cd激活的途径,抑制肿瘤抑制因子BRCA 1和p53的功能,抑制DNA损伤诱导的细胞凋亡和细胞周期阻滞,诱导上皮细胞增殖和乳腺癌的发生和发展。本研究从以下三个方面对这一假说进行了验证:(1)探讨汞诱导PP 2Cd活化的机制:(2)探讨PP 2Cd使乳腺上皮细胞BRAC 1去磷酸化并拮抗p53乙酰化的分子机制;(3)通过链脲佐菌素(STZ)诱导的或高脂饮食,在体内表征高血糖对乳腺癌的发展和化疗的影响。STZ诱导的糖尿病裸鼠携带MCF-7细胞和来自糖尿病或非糖尿病患者的乳腺癌标本。这些研究为研究这种连接糖尿病和乳腺癌的新机制奠定了基础,目的是定义一种新的途径并提供额外的治疗靶点。乳腺癌尤其影响到很大一部分非裔美国人和西班牙裔妇女,并构成社会的重大财政负担。因此,研究高血糖对致癌信号网络的影响是一个具有相当大的翻译意义的新问题,将是揭示这种健康差异的重要一步。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yong Wu其他文献
Yong Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yong Wu', 18)}}的其他基金
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer
一种治疗糖尿病相关乳腺癌的新型代谢重编程策略
- 批准号:
10409714 - 财政年份:2020
- 资助金额:
$ 35.88万 - 项目类别:
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancer
一种治疗糖尿病相关乳腺癌的新型代谢重编程策略
- 批准号:
10615233 - 财政年份:2020
- 资助金额:
$ 35.88万 - 项目类别:
Mechanisms behind hyperglycemia-associated breast cancer risk and progression
高血糖相关乳腺癌风险和进展背后的机制
- 批准号:
9113516 - 财政年份:2015
- 资助金额:
$ 35.88万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Research Grant